LANXESS AG UNSP.ADR 1/5 Total Liabilities
LANXESS AG UNSP.ADR 1/5 total liabilities. Based on the latest financial reports, LANXESS AG UNSP.ADR 1/5 (LX9B) has total liabilities worth €4.28 Billion EUR (≈ $5.00 Billion USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See LANXESS AG UNSP.ADR 1/5 liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of LANXESS AG UNSP.ADR 1/5 (2021–2024)
Total liabilities of LANXESS AG UNSP.ADR 1/5 from 2021 to 2024. This chart illustrates how LANXESS AG UNSP.ADR 1/5's total liabilities have evolved over time, based on quarterly financial data. Check LANXESS AG UNSP.ADR 1/5 (LX9B) asset resilience to evaluate the company's liquid asset resilience ratio.
LANXESS AG UNSP.ADR 1/5 Competitors by Total Liabilities
The table below lists competitors of LANXESS AG UNSP.ADR 1/5 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Boston Beer Company Inc
NYSE:SAM
|
USA | $335.62 Million |
|
Shanghai Feilo Acoustics Co Ltd
SHG:600651
|
China | CN¥1.61 Billion |
|
Xiamen ITG Group Corp Ltd
SHG:600755
|
China | CN¥102.92 Billion |
|
SES S. A.
PA:SESG
|
France | €7.65 Billion |
|
Cloetta AB (publ)
ST:CLA-B
|
Sweden | Skr4.80 Billion |
|
Sirius Real Estate Ltd
JSE:SRE
|
South Africa | ZAC1.66 Billion |
|
Braveheart Bio, Inc. Common Stock
NASDAQ:BRVE
|
USA | $222.86 Million |
|
Hope Bancorp Inc
NASDAQ:HOPE
|
USA | $16.70 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down LANXESS AG UNSP.ADR 1/5's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of LANXESS AG UNSP.ADR 1/5.
Liquidity & Leverage Metrics
LANXESS AG UNSP.ADR 1/5 Total Liabilities Ratios Explained
LANXESS AG UNSP.ADR 1/5 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LANXESS AG UNSP.ADR 1/5's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LANXESS AG UNSP.ADR 1/5 (2021–2024)
The table below shows the annual total liabilities of LANXESS AG UNSP.ADR 1/5 from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €5.12 Billion ≈ $5.98 Billion |
-0.76% |
| 2023-12-31 | €5.16 Billion ≈ $6.03 Billion |
-24.81% |
| 2022-12-31 | €6.86 Billion ≈ $8.02 Billion |
+1.39% |
| 2021-12-31 | €6.77 Billion ≈ $7.91 Billion |
-- |
About LANXESS AG UNSP.ADR 1/5
LANXESS Aktiengesellschaft, a specialty chemicals company, engages in the development, manufacture, and marketing of chemical intermediates, additives, and consumer protection products worldwide. It operates through three segments: Consumer Protection, Specialty Additives, and Advanced Intermediates. The company provides material protection products; disinfectant, hygiene, and preservative soluti… Read more